LIVE MARKETS
--:--:-- ET
Testsite Thoughts, stories and ideas. 40 filings/day — zero noise
Other ● Checked against the source
SCNI

SCINAI Ends PC111 Arrangements to Refocus on NanoAb and CDMO Work

Scinai says it has concluded its PC111 arrangements and will redirect capital to its NanoAb platform and expanding CDMO business.

TickersSCNI Other
DeskOther
PublishedSep 8, 2026 · 13:53 ET
AccessPro story
Scinai Immunotherapeutics chief executive Amir Reichman.
Source: Wikimedia